Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02272270 · ClinicalTrials.gov registry record · Phase 1
Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)
A Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02272270 is a Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 25 participants.
The verdict
NCT02272270, a Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This will be an open label, single arm study. Subjects with newly diagnosed high grade glioma will begin minocycline one week prior to beginning postoperative chemoradiation and continue it until progression, intolerance, or the end of adjuvant temozolomide, whichever comes first.
Interventions
- DRUG Minocycline with chemoradiation (temozolomide and radiation therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-10-27 |
| Est. Completion | 2018-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02272270
The ClinicalTrials.gov registry entry for NCT02272270 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Minocycline with chemoradiation (temozolomide and radiation therapy) is the first listed.
NCT02272270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02272270 about?
NCT02272270 is a clinical study titled "Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)". This will be an open label, single arm study. Subjects with newly diagnosed high grade glioma will begin minocycline one week prior to beginning postoperative chemoradiation and continue it until progression, intolerance, or the end of adjuvant temozolomide, whichever comes first.
What is the current status of trial NCT02272270?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-10-27. Estimated completion is 2018-02-18.
What interventions are being tested in trial NCT02272270?
The interventions under investigation include: Minocycline with chemoradiation (temozolomide and radiation therapy) (DRUG).
Who is sponsoring clinical trial NCT02272270?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.